Genmab — Juni 2016
-
trial results compare favourably in quite a dramatic fashion on all endpoints, with a profoundly better benefit on PFS (HR 0.37 vs 0.69) and CR rate (43% vs 32%). The ASPIRE trial demonstrated that Kyprolis delayed progression by a median of 8 months vs Revlimid/dex. Mature Pollux results seem likely to significantly exceed this level of benefit. Importantly, Darzalex treatment also seems to come with significantly less toxicity.
-
@Helge Jeg kan se, kursmålene står kronologisk som de bliver opdateret. Er det muligt, at de finanshuse, som følger Genmab, kan stå med opdaterede kursmål, så jyske eksempelvis ikke står 4 gange i træk med forskellige kursmål ? Dette for at lette overblikket og aktualitet? http://www.proinvestor.com/kurstargets/GEN.CO
-
Hvad er det årlige salg af Kyprolis?
-
-
Selvfølgelig Legolas. Jeg spørger maskinrummet om de kan ændre det.
-
Ditto her fra.
-
@JKY og Helge. My plessure
-
tusind tak for info MUFC - du gør en forbilledlig indsats!
-
tak i lige made dingle
-
måde
-
-
alligevel friskt at udtale, at man betaler for dara og får resten af pipelinen gratis - når man lige hæver til 1460...
-
Dr. Saad Usmani fra ASCO om daratumumab subcut phase 1b studyhttps://www.youtube.com/watch?v=fMyMVRLAdMM
-
Så vi kan forvente data på ASH for subcut studiet
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind